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Abstract: Rivaroxaban (Bayer AG, Leverkusen, Germany) is a highly selective direct inhibitor 
of factor Xa. It has completed Phase III clinical trials evaluating its efficacy and safety against 
enoxaparin in the prophylaxis against venous thromboembolism (VTE) in orthopedic patients 
following primary total hip and total knee arthroplasty. Rivaroxaban has been extensively 
studied worldwide in 12,729 patients in the Regulation of Coagulation in Major Orthopedic 
Surgery Reducing the Risk of DVT and PE (RECORD) program. Pivotal clinical trials have 
demonstrated the superior efficacy in reducing total VTE in comparison with both the North 
American and European regimens of enoxaparin. Safety of the drug was found to be excellent, 
with no demonstrable cardiovascular or hepatic effects and no statistically significant increase 
in major bleeding. A pooled analysis of data collected on the patients from the four RECORD 
trials revealed rivaroxaban to be the first antithrombotic agent to demonstrate superiority over 
another antithrombotic (enoxaparin) in reducing symptomatic VTE and all-cause mortality. 
While there was a significant difference in the composite safety endpoint of major and clinically 
relevant nonmajor bleeding in the pooled analysis with the use of rivaroxaban compared with 
enoxaparin, there was no significant difference in major bleeding or in any other bleeding.
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Introduction
Venous thromboembolism (VTE) is the most frequent serious complication following total 
hip and total knee arthroplasty. In the absence of thromboprophylaxis, 50% to 60% of these 
patients will develop either deep vein thrombosis (DVT) or pulmonary embolism (PE). 
Because patients following total joint arthroplasty are at very highest risk for the development 
of VTE, the use of routine thromboprophylaxis has been recommended in these patients by a 
number of nationally and internationally recognized entities including the American College 
of Chest Physicians, the American Academy of Orthopaedic Surgeons, the International 
Surgical Thrombosis Forum, and the US Centers for Medicare and Medicaid Services.
Contemporary antithrombotic strategies
Current guideline recommendations for thromboprophylaxis involve the use of vitamin 
K antagonists (VKA), low-molecular-weight heparins (LMWH), aspirin, or fonda-
parinux, an indirect inhibitor of factor Xa.1,2,3 While aspirin has been advocated by a 
number of organizations for thromboprophylaxis,3 this agent functions principally as 
an inhibitor of platelet aggregation rather than as an antithrombotic agent. The use Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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of VKAs is associated with extremely variable patient-
to-patient response, delay in onset of action, extensive food 
and drug interactions, and the need for monitoring and dose 
adjustment to target the international normalized ratio val-
ue.3 Both LMWHs and fondaparinux require subcutaneous 
injection for drug administration. This can significantly 
affect patient acceptance and compliance during extended 
prophylaxis and in circumstances depending on patient 
self-administration.4
A new antithrombotic agent
Rivaroxaban is a highly selective direct inhibitor of factor 
Xa that has completed Phase III clinical trials evaluating 
its efficacy and safety against enoxaparin in the pro-
phylaxis against VTE in orthopedic patients following 
primary total hip and total knee arthroplasty. Rivaroxaban 
has a half-life of approximately 9 hours, with a rapid 
onset of action, reaching maximum serum concentration 
in ,2 hours. It has very   predictable pharmacokinetics 
and pharmacodynamics, and has no significant food or 
drug interactions. Approximately one-third of the drug is 
metabolized by the liver and/or through gastrointestinal 
transit and eliminated via the fecal route; the remaining 
two-thirds is cleared via renal excretion.5–7 Rivaroxaban 
is administered orally at a fixed dose, unmonitored, once 
daily. As such, the use of the drug provides a very simple 
regimen for both the patient and the physician, with a route 
of administration that is readily embraced by the patient, 
reducing compliance concerns associated with parenteral 
drug administration.
Clinical trial results
Rivaroxaban has been extensively studied in 12,729 
patients worldwide in the RECORD Program (REgulation 
of Coagulation in major Orthopaedic surgery reducing the 
Risk of DVT and PE). This represents the largest ortho-
pedic clinical development program ever conducted. Four 
Phase III pivotal trials evaluated the safety and efficacy 
of rivaroxaban against the active comparator, enoxaparin. 
All four clinical trials shared the same basic, prospective, 
randomized, double-blind study design template, as well 
as the same blinded, independent adjudication committee 
for outcomes. These trials also shared the same primary 
efficacy endpoint, which was a composite of symptomatic 
DVT, nonfatal PE, and all-cause mortality. All four trials 
also shared common safety endpoints for major bleeding, 
major bleeding including the surgical site requiring reop-
eration, major and clinically relevant nonmajor bleeding, 
and any bleeding. This allowed a pooled data analysis from 
the .12,000 patients of the four pivotal RECORD trials 
to be performed.
Two of these trials (RECORD1 and 2) dealt with 
patients following total hip arthroplasty, and two 
(RECORD3 and 4) dealt with patients following total 
knee arthroplasty. RECORD1 compared rivaroxaban 
10 mg once daily for 5 weeks against enoxaparin 40 mg 
once daily also for 5 weeks.8 RECORD2 evaluated the 
safety and efficacy of rivaroxaban 10 mg once daily for 5 
weeks against enoxaparin 40 mg once daily for 10–14 days 
followed by oral placebo.9 In RECORD3, rivaroxaban 
10 mg once daily for 10–14 days was compared against 
enoxaparin 40 mg once daily also for 10–14 days.10 In 
RECORD4, rivaroxaban 10 mg once daily for 10–14 days 
was compared against enoxaparin 30 mg twice daily also 
for 10–14 days.11 In all four RECORD trials, rivaroxa-
ban was found to be   statistically significantly superior 
to enoxaparin in the reduction of total VTE (the primary 
efficacy endpoint). Additionally, in RECORD1, 2, and 3, 
rivaroxaban was superior in reducing major VTE (a com-
posite of proximal DVT, symptomatic PE, and all-cause 
mortality), and in RECORD2 and 3, superior in reducing 
symptomatic VTE (a composite of symptomatic DVT, 
symptomatic PE, and VTE-related death). RECORD4 
is notable in that it represents the only clinical trial ever 
to demonstrate superior efficacy of any antithrombotic 
agent in comparison with the North   American regimen 
of enoxaparin (30 mg subcutaneously twice daily). The 
superior efficacy of rivaroxaban was achieved without a 
statistically significant increase in major bleeding, which 
was ,0.7% in all trials. Table 1 summarizes the efficacy 
results from the four RECORD Trials.8–11 Table 2 Summa-
rizes key primary as well as composite safety   endpoints. 
There was no   statistically significant difference in major 
bleeding, or difference in clinically relevant nonmajor 
bleeding.12
Table 1 Summary table ReCORD trials: RRR (%) rivaroxaban vs 
enoxaparin
Total  
VTE
Major  
VTE
Symptomatic  
VTE
Major  
bleeding*
ReCORD1 77 88 NS NS
ReCORD2 79 88 80 NS
ReCORD3 49 62 66 NS
ReCORD4 31 NS NS NS
Note: *Major bleeding ,0.7% in all trials in all groups.
Data from Lassen et al poster.12
Abbreviations: NS, no statistically significant difference; VTE, venous thromboem­
bolism.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Pooled analysis
A pooled analysis of the data from RECORD1, 2, 3, and 4 was 
performed to compare rivaroxaban with enoxaparin regimens 
in reducing the incidence of efficacy and safety-related end-
points across the four pivot trials. A pre-specified integrated 
analysis strategy for symptomatic event composites across 
the RECORD1–4 studies was utilized. Because the number 
of VTE events was expected to be low in any of the individual 
RECORD studies, pooling was utilized to increase statistical 
precision, and to allow for a better assessment of clinically 
relevant endpoints. Because the RECORD trials differed in the 
duration of drug administration, treatment duration and total 
follow-up duration, three population pools were   evaluated. 
The Active Treatment Pool represented that group of patients 
receiving drug administration up to 12 ± 2 days. The Total 
Treatment Duration Pool included all patients during their 
treatment periods (from day 12 ± 2 days to day 35 ± 4 days). 
The total study duration pool represented all patients up to and 
including the final follow-up (from day 42 to 65). Figure 1 
illustrates the pooled analysis study design.13
The prespecified primary efficacy outcome in this pooled 
analysis was a composite of symptomatic DVT and nonfatal 
Table 2 Safety data at follow-up day 12 ± 2 days
Rivaroxaban 
(n = 6183)  
(n) %
Enoxaparin 
(n = 6200)  
(n) %
Hazard ratio 
(95% CI)
P-value
Major bleeding 24 (0.4) 13 (0.2) 1.84 (0.94–3.62) 0.08
  Bleeding leading to reoperation 12 (0.2) 7 (0.1) – –
    Clinically overt extra-surgical site bleeding leading  
to – transfusion of .2 units of whole blood  
or PRBC
8 (0.1) 1 (,0.1) – –
Clinically relevant nonmajor bleeding 177 (2.9) 145 (2.3) 1.22 (0.98–1.52) 0.08
  Surgical site bleeding 47 (0.8) 49 (0.8) – –
  excessive wound hematoma 53 (0.9) 58 (0.9) – –
Major bleeding plus clinically relevant nonmajor bleeding 201 (3.2) 158 (2.5) – 0.039
Data from Lassen et al poster.12
Abbreviation: PRBC, packed red blood cells.
Rivaroxaban Follow-up
Enoxaparin Follow-up
Rivaroxaban
Enoxaparin Follow-up
Follow-up
Rivaroxaban
Follow-up
Day 42
(42–47)
Follow-up
Day 65
(61–65)
Day 12
(10–14)
Day 1
Enoxaparin Placebo
Follow-up Record 1
Hip
Record 2
Hip
Record 3
Knee
Record 4
Knee
Total study
duration pool
Day 12
(10–14)
Day 35
(31–39)
Rivaroxaban
Rivaroxaban
Enoxaparin Follow-up
Follow-up
Follow-up
Day 12 ± 2 active
treatment pool
Total treatment
duration pool
Figure 1 Pooled analysis design. 
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PE, as well as all-cause mortality. All symptomatic events 
were confirmed and centrally adjudicated. Other outcomes 
evaluated included all-cause mortality; a post-hoc analysis 
of a composite of PE and all-cause mortality; and a post-hoc 
analysis of a composite of all major clinical outcomes (death, 
myocardial infarction, stroke, symptomatic VTE, and major 
bleeding). Safety outcomes consisted of the   prespecified 
treatment-emergent bleeding endpoints of major   bleeding: 
major bleeding including surgical site bleeding, major 
bleeding and clinically relevant nonmajor bleeding, and any 
bleeding. Other safety endpoints included adverse events, 
including cardiovascular events.
Rivaroxaban demonstrated a 58% reduction in the 
  primary efficacy outcome (symptomatic VTE and all-cause 
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Figure 2 Total treatment duration pool efficacy outcome.
Notes: Homogeneity test, P = 0.31; safety population, n = 12,383.
Abbreviations: VTe, venous thromboembolism; RRR, relative risk reduction; HR; 
hazard ratio.
Primary efficacy outcome
Day 12 ± 2 active treatment pool
Symptomatic VTE + all-cause mortality
0
0.5
1.0
1.5
Enoxaparin
regimens
82/6200
Rivaroxaban
regimens
35/183
1.0%
0.5%
RRR* = 52% 
HR = 0.48 (95% CI: 0.31–0.75)
P < 0.001
I
n
c
i
d
e
n
c
e
 
(
%
)
Figure 3 Active treatment pool efficacy outcome.
Notes: Homogeneity test, P = 0.431; safety population, n = 12,383.
Abbreviations: VTe, venous thromboembolism; RRR, relative risk reduction; HR; 
hazard ratio.
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Figure 4 Total study duration efficacy outcome.
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mortality) for the Total Treatment Duration Pool compared 
with enoxaparin in the primary population for analysis 
(Figure 2). In the Active Treatment Pool, there was a 52% 
reduction in the primary efficacy outcome with rivaroxaban 
compared with enoxaparin (hazard ratio [HR] 0.48; 95% 
confidence interval [CI] 0.31–0.75) (Figure 3). Rivaroxa-
ban was also found to significantly reduce the incidence 
of symptomatic VTE and all-cause mortality in the Total 
Study Duration Pool up to and including final follow-up 
(HR 0.49; 95% CI 0.35–0.69) (Figure 4). Additionally, 
rivaroxaban significantly improved the composite outcome 
of symptomatic VTE, cardiovascular events, all-cause 
mortality, and major bleeding compared with enoxaparin 
regimens. There were no demonstrable adverse effects 
on hepatic function (Table 3). There was no statistically 
significant difference in any bleeding, major bleeding, or 
major plus clinically relevant nonmajor (CRNM) bleeding 
at day 12 ± 2 days and at follow-up. There was a signifi-
cant difference in major plus CRNM at day 35 (including 
the placebo phase of RECORD2) favoring the use of 
enoxaparin in the safety analysis of composite bleeding 
endpoints (rivaroxaban 158/12,383 [2.55%]; enoxaparin 
197/12,383 [3.19%], P = 0.039 [analyzed using Cox 
regression model]).12
Discussion
Rivaroxaban is a new oral antithrombotic agent that is a 
highly selective direct inhibitor of factor Xa. It has been 
designed with a simple once-a-day regimen to be used 
across a broad spectrum of the population at a fixed dose, 
  unmonitored. Pivotal clinical trials have demonstrated 
the superior efficacy in reducing total VTE in comparison 
with both the North American and European regimens 
of enoxaparin. Safety of the drug was found to be excellent 
with no demonstrable   cardiovascular or hepatic effects, 
and no statistically significant increase in major bleeding 
or in any bleeding. Although a statistically significant 
difference was found in major plus CRNM at day 35 
favoring the use of enoxaparin in the safety analysis of 
composite   bleeding   endpoints, in the clinical setting, this 
finding may not   represent a relevant factor for the surgeon 
in terms of   surgical site   complications (no statistically 
significant   differences were found in bleeding leading to 
  reoperation, prolonged wound drainage, hemarthrosis, or 
wound dehiscence) and no statistically significant differ-
ence was found in postoperative infection rate between 
the rivaroxaban and enoxaparin groups.12 The use of 
pharmacologic thromboprophylaxis as a risk factor for 
postoperative   bleeding and prolonged wound drainage lead-
ing to infection is a concern of some orthopedic surgeons, 
although a causal relationship has never been established, 
and a recent review of the peer-reviewed literature also 
does not support this association.14 A pooled analysis of 
the 12,729 patients from the four RECORD   trials revealed 
rivaroxaban to be the first antithrombotic agent to demon-
strate superiority over another antithrombotic (enoxaparin) 
in reducing symptomatic VTE and all-cause mortality. 
A pharmacoeconomic analysis of the efficacy and safety of 
rivaroxaban compared with the use of enoxaparin indicates 
that rivaroxaban has the potential to be cost effective in 
reducing costs associated with the prophylaxis and treat-
ment of thromboembolic events in postoperative hip and 
knee replacement patients.15,16
In summary, rivaroxaban appears to have the potential 
to provide a safe, convenient, and effective method for 
  prophylaxis against VTE in the high-risk group of orthopedic 
patients following total hip and knee arthroplasty.
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